Flomics Biotech, finalist in the Global Startup Awards
The company has focused on the study of circulating RNA for the early detection of cancer
Since its foundation in 2018, Flomics Biotech has focused on the study of circulating RNA for the early detection of cancer. With the growing need of non-invasive biomarkers of disease, and in particular of cancer, the initiative proposed by Flomics Biotech to study liquid biopsies has raised the interest of multiple national and international organizations.
Because of these reasons, in 2020, Flomics was nominated and chosen as the best “newcomer” by the South Europe Startup Awards. This organism represents the regional branch of the Global Startup Awards, an initiative led by the Global Startup Ecosystem and present today in 113 countries, four continents and it is constantly growing.
The following November 16th and 17th, the Global Startup Awards will celebrate an event in Denmark to choose the best startups of 2020, globally, in categories such as Startup or Founder of the year. As winner of the regional event, Flomics has been selected as a finalist for the Best Newcomer Award, an honor that will be granted through the combination of the popular vote and a jury of experts. If you believe in our goals and want to support us, you can vote for us through this link.